| Patient | Gwen Ifill |
|---|---|
| Date of birth | 1965-09-29 |
| Identifiers | MRN HR-ML032-SYN; SSN (made up) 000-32-5814 |
| Document date | 2026-01-20 |
| Author | Lorna Achebe-Price, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Endometrial biopsy result and gynecologic oncology consultation. [S]
Ms. Ifill returns two weeks after her first visit. The transvaginal ultrasound two days after that visit showed a 16 mm heterogeneous endometrium with internal blood flow and two small fibroids. The endometrial biopsy taken at the first visit, telephoned to her four days later, shows endometrioid adenocarcinoma, FIGO grade 2, with loss of MLH1 and PMS2 staining and a wild-type p53 pattern. CT of the chest, abdomen and pelvis the next week showed an enlarged right external iliac lymph node and an enlarged left para-aortic node, with no disease in the liver, lungs, bones or peritoneum. Dr. Delacroix of gynecologic oncology saw her this morning. The bleeding has lessened to occasional spotting. She has no pain, bowel or bladder change, leg swelling or weight loss. She says she is shaken but glad the answer came quickly, and wants to keep working through treatment if she can. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Biopsy | Endometrioid adenocarcinoma, FIGO grade 2; MLH1 and PMS2 lost; p53 wild-type |
| Imaging | Ultrasound: endometrium 16 mm, heterogeneous. CT: enlarged right external iliac and left para-aortic nodes; no distant disease |
| Symptoms | Spotting only; no pain |
| Coordination | Gynecologic oncology seen today; surgery in two weeks |
| Her questions | Whether the nodes mean the cancer has spread, whether it is inherited, and whether she can keep working |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, night sweats or weight loss |
| Genitourinary | Positive | Occasional spotting; no urinary symptoms |
| Gastrointestinal | Negative | No abdominal pain or change in bowel habit |
| Respiratory | Negative | No cough or breathlessness |
| Cardiovascular | Negative | No leg swelling or calf pain |
| Psychiatric | Positive | Worried and sleeping less; PHQ-9 6 and GAD-7 7; no thoughts of self-harm |
6 systems reviewed. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-01-20 | Body height | 165 | cm | S |
| 2026-01-20 | Body weight | 74.2 | kg | S |
| 2026-01-20 | Body mass index (BMI) [Ratio] | 27.3 | kg/m2 | S |
| 2026-01-20 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-01-20 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-01-20 | Heart rate | 84 | /min | S |
| 2026-01-20 | Respiratory rate | 16 | /min | S |
| 2026-01-20 | Body temperature | 36.6 | Cel | S |
| 2026-01-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-20 | Hemoglobin [Mass/volume] in Blood | 12.1 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-01-20 | Leukocytes [#/volume] in Blood by Automated count | 6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-01-20 | Neutrophils [#/volume] in Blood by Automated count | 3.6 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-01-20 | Platelets [#/volume] in Blood by Automated count | 274 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-01-20 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-01-20 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-01-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-01-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-01-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | 7-35 U/L | Normal | S |
| 2026-01-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 8-35 U/L | Normal | S |
| 2026-01-20 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-01-20 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-01-20 | Cancer Ag 125 [Units/volume] in Serum or Plasma | 28 | U/mL | <=35 U/mL | Normal | S |
| 2026-01-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-01-20 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | {score} | S |
Vital signs recorded on 2026-01-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 74.2 kg; blood pressure 132/82, pulse 84 |
| Abdomen | Soft, non-tender; no mass or fluid |
| Pelvic | Examined with Dr. Delacroix and a chaperone: small amount of blood at the cervical os; cervix normal; uterus mobile, slightly enlarged; no adnexal mass or parametrial thickening |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Extremities | No leg swelling |
| Psychiatric | Composed, direct and focused; anxious when talking about the nodes |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review booked | resolved | confirmed | N95.0 | S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded by the diagnosis at the gynecologic oncology consultation. |
| Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient (loss of MLH1 and PMS2 staining), p53 wild-type pattern, on office endometrial biopsy, with enlarged right pelvic and para-aortic lymph nodes on CT; surgical staging planned; synthetic modern detail linked to her publicly reported endometrial cancer | active | confirmed | C54.1 | S — Synthetic histology, molecular result and extent; her family gave endometrial cancer as the cause of death (D), and nothing more about it was made public. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Evaluation of any postmenopausal bleeding | At the first report | Up to date | Examined and sampled at the first visit, without a waiting period |
| Laboratory | Endometrial tissue sampling | At the first evaluation of postmenopausal bleeding, with transvaginal ultrasound | Up to date | Office biopsy at the first visit: endometrioid adenocarcinoma, FIGO grade 2 |
| Imaging | Transvaginal ultrasound | At the first evaluation, together with sampling | Up to date | Endometrium 16 mm, heterogeneous, with blood flow; two small intramural fibroids |
| Imaging | CT of the chest, abdomen and pelvis | Before primary treatment when high-grade or extrauterine disease is suspected | Up to date | Enlarged right external iliac and left para-aortic nodes; no distant disease |
| Laboratory | Mismatch repair immunohistochemistry (universal Lynch syndrome tumor screen) | At diagnosis, on every endometrial cancer | Up to date | Loss of MLH1 and PMS2; MSH2 and MSH6 retained |
| Laboratory | MLH1 promoter methylation | Reflex when MLH1 is lost | Ordered | Sent on the biopsy today |
| Laboratory | p53 immunohistochemistry and POLE sequencing (molecular classification) | At diagnosis or on the surgical specimen | Ordered | p53 wild-type pattern on the biopsy; POLE to be sequenced on the surgical specimen |
| Laboratory | CA-125 | At diagnosis; afterwards only if raised at diagnosis | Completed today | 28 U/mL, normal; not to be repeated routinely |
| Laboratory | Blood count, chemistry and liver tests before surgery | Within 30 days before surgery | Completed today | Hemoglobin 12.1 g/dL, white cells 6.0, neutrophils 3.6, platelets 274; sodium 139, potassium 4.3, creatinine 0.80 mg/dL, eGFR 84; ALT 19, AST 21, bilirubin 0.5, albumin 4.1 |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before systemic cancer treatment | Ordered | Hepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody, and HIV drawn today |
| Referral | Gynecologic oncology | Before any surgery for endometrial cancer | Completed today | Seen this morning; recommendations in the consultation note |
| Referral | Genetic counseling | At diagnosis when the tumor screen is abnormal | Due | After the methylation result, at the next visit |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, each treatment phase, and when symptoms change | Completed today | PHQ-9 6 and GAD-7 7, mild, with worry about the diagnosis; no thoughts of self-harm |
| Self-management | Information, support and privacy | At diagnosis and throughout | Completed today | Plain explanation with written information; she chose who would be told and asked that notes go only to her clinicians |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Updated Guidance Regarding the Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Individuals With Postmenopausal Bleeding. Obstet Gynecol 2026;148(1):e87-e91 (PMID 41990335) (2026); Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol 2018;131(5):e124-e129 (PMID 29683909) (2018); Berek JS, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023;162(2):383-394 (PMID 37337978) (2023); ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol 2014;124(5):1042-1054 (PMID 25437740) (2014); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020 (2020); Clarke MA, et al. Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype. JAMA Oncol 2022;8(6):895-903 (PMID 35511145) (2022); Doll KM, et al. Assessment of Prediagnostic Experiences of Black Women With Endometrial Cancer in the United States. JAMA Netw Open 2020;3(5):e204954 (PMID 32412636) (2020); CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Surgery in two weeks with Dr. Delacroix. Primary care review three weeks after surgery with the final pathology, the methylation and POLE results, and genetic counseling. Call for heavy bleeding, fever, or leg swelling. Next scheduled visit 2026-02-24: review three weeks after surgical staging: final pathology and molecular class, genetic counseling, and the first cycle of dostarlimab with carboplatin and paclitaxel. [S]